US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Park Hotels & Resorts Inc.

10.00

+0.01000.10%

Post-market: 10.040.0400+0.40%17:59 EDT

Volume:3.48M

Turnover:34.70M

Market Cap:2.02B

PE:9.90

High:10.03

Open:9.98

Low:9.82

Close:9.99

Loading ...

Overview Company News Filings

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

IIPR's Q4 Earnings Coming Up: Key Factors to Impact the Stock

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

RANI: Impressive Bioavailability for RT-116

Zacks Small Cap Research

Park Hotels & Resorts Inc expected to post earnings of 6 cents a share - Earnings Preview

Park Hotels & Resorts (PK) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Park Hotels & Resorts Inc. (PK): Among the Best Hotel Stocks to Buy According to Analysts

Press Release: Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Press Release: Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Zacks Market Edge Highlights: WASH, SPG PAA, PK and ETD

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PK/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","market":"US","secType":"STK","nameCN":"Park Hotels & Resorts Inc.","latestPrice":10,"timestamp":1745611200000,"preClose":9.99,"halted":0,"volume":3479513,"hourTrading":{"tag":"盘后","latestPrice":10.04,"preClose":10,"latestTime":"17:59 EDT","volume":137436,"amount":1374381.11,"timestamp":1745618344339},"delay":0,"floatShares":197724425,"shares":201864175,"eps":1.01,"marketStatus":"Market Closed","change":0.01,"latestTime":"04-25 16:00:00 EDT","open":9.98,"high":10.0253,"low":9.815,"amount":34696301.392261,"amplitude":0.021051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.01,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":9.99,"dividendRate":0.14,"preHourTrading":{"tag":"盘前","latestPrice":10.18,"preClose":9.99,"latestTime":"09:25 EDT","volume":291,"amount":2960.915397,"timestamp":1745587526246},"postHourTrading":{"tag":"盘后","latestPrice":10.04,"preClose":10,"latestTime":"17:59 EDT","volume":137436,"amount":1374381.11,"timestamp":1745618344339},"volumeRatio":0.8356835002679648,"impliedVol":0.5641,"impliedVolPercentile":0.812},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PK\",,,,,undefined,":{"symbol":"PK","floatShares":197724425,"roa":"2.35%","roe":"6.14%","lyrEps":1.019323,"volumeRatio":0.8356835002679648,"shares":201864175,"dividePrice":1.4,"high":10.0253,"amplitude":0.021051,"preClose":9.99,"low":9.815,"week52Low":8.27,"pbRate":"0.55","psRate":"0.77","week52High":16.78,"institutionHeld":0,"latestPrice":10,"eps":1.01,"divideRate":0.14,"volume":3479513,"delay":0,"ttmEps":1.01,"open":9.98,"prevYearClose":14.07,"prevWeekClose":9.83,"prevMonthClose":10.68,"prevQuarterClose":10.68,"fiveDayClose":9.83,"twentyDayClose":11.15,"sixtyDayClose":13.35,"earningDate":1746374400000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PK\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512829432","title":"BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2512829432","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512829432?lang=en_us&edition=fundamental","pubTime":"2025-02-20 05:05","pubTimestamp":1739999100,"startTime":"0","endTime":"0","summary":"Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 2025. 4Q 2024 Total Revenues of $747 million ; FY 2024 Total Revenues of $2.85 billion . Conference Call and Webcast Scheduled Today at 4:30 p.m. ET. SAN RAFAEL, Calif., Feb. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc.  today announced financial results for the fourth quarter and full year ended December31, 2024.GAAP Net Income increased by $105 million to $125 million in the fourth quarter of 2024 compared to the same period in 2023. The increase was primarily due to higher gross profit driven by the factors noted above and reduced research and development (R&D) sp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biomarin-reports-fourth-quarter-full-210500837.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biomarin-reports-fourth-quarter-full-210500837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4585","IE00B19Z3581.USD","IE00BD4GTT62.SGD","IE0002270589.USD","BK4159","IE00BD4GTW91.USD","BK4588","IE00BD4GTV84.USD","PK","BK4566","BK4181","BK4208","BK4218","LU2380233275.USD","BK4139","BMRN","CNP","CAGR"],"gpt_icon":0},{"id":"2512104227","title":"JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2512104227","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512104227?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Japanese Patent Office  in January 2025. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of-matter, surface coatings and pharmaceutical compositions for use in methods of treatingGram-positive bacterial infection. This is the latest in the series of granted patents and pending patent applications that Acrux has filed to protect its proprietary technologies in the field of antimicrobials.To date, Acurx has obtained three U.S. patents, one Israeli patent and now one Japanese patent, in each case, which cover the ACX-375C program, relating to DNA Polymerase IIIC Inhibitors, with other country-level filings in process.The primary efficacy analysis will be performed using a Modified Intent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jpo-grants-acurx-pharmaceuticals-patent-130000150.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jpo-grants-acurx-pharmaceuticals-patent-130000150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4135","BK4109","BK4585","BK4563","BK4139","BK4588","ECC","IDSA","VRE","MAA","DNA","ACXP","BK4194","BK4539","BK4215","BK4181","GAIN","BK4218"],"gpt_icon":0},{"id":"2512860116","title":"Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512860116","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512860116?lang=en_us&edition=fundamental","pubTime":"2025-02-19 06:52","pubTimestamp":1739919120,"startTime":"0","endTime":"0","summary":"Dallas, Texas-- - Incannex Healthcare Inc. : Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. . During the second quarter of fiscal year 2025, Incannex Healthcare Inc. reported R&D costs of $1.4M, a decrease from $2.6M in the same period of the previous year. This reduction was primarily due to the completion of the IHL-42X safety and pharmacokinetics clinical trial and the reallocation of resources from the Phase 2 IHL-675A Australia study to a larger U.S. Phase 2 study. The Company recovered 68.3% of these costs with an R&D tax incentive of $0.956 million. The net loss for the quarter was $5.9M, compared to $5.2M in the same period of the previous year.To view the full announcement, including downloadable images, bios, and more, click here.Incannex secured a strategic financing agreement with Arena Investors, which includes a $50M ELOC with Arena Business Solutions.IHL-42X had positive top-line results from a pharmacokinetics and safety study. The study d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/stonegate-updates-coverage-incannex-healthcare-225200614.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/stonegate-updates-coverage-incannex-healthcare-225200614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4218","BK4181","IXHL","BK4007"],"gpt_icon":0},{"id":"2512678831","title":"IIPR's Q4 Earnings Coming Up: Key Factors to Impact the Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2512678831","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512678831?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:55","pubTimestamp":1739890500,"startTime":"0","endTime":"0","summary":"Innovative Industrial Properties, Inc. IIPR, a leading real estate investment trust  specializing in the acquisition, ownership and management of specialized properties leased to experienced, state-licensed operators for their regulated cannabis facilities, is set to announce its fourth-quarter and full-year 2024 earnings results on Feb. 19, after market close.See the Zacks Earnings Calendar to stay ahead of market-making news.In the last reported quarter, Innovative Industrial reported adjusted funds from operations  per share of $2.25, which missed the Zacks Consensus Estimate of $2.29. Results reflected lower-than-expected revenues.Over the last four quarters, IIPR’s adjusted FFO per share surpassed the consensus mark on two occasions for as many misses, with the average beat being 0.02%. The graph below depicts the surprise history of the company:. Innovative Industrial Properties, Inc. price-eps-surprise | Innovative Industrial Properties, Inc. Quote","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iiprs-q4-earnings-coming-key-145500166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RHP","PK","IIPR"],"gpt_icon":0},{"id":"2512920166","title":"Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2512920166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512920166?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:50","pubTimestamp":1739890200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 09:50 ET (14:50 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","LU0648001328.SGD","LU0162691827.USD","LU0052756011.USD","LU0128525689.USD","PK","LU0980610538.SGD","LU0708994859.HKD","LU1069347547.HKD","LU0320765489.SGD","LU1267930227.SGD","LU0417517546.SGD","LU1814569148.SGD","BK4181","LU1201861249.SGD","LU0310800965.SGD","BK4504","LU0971096721.USD","LU1074936037.SGD","LU1267930490.SGD","LU1267930573.SGD","LU0787776722.HKD","LU0149725797.USD","LU2236285917.USD","LU0310800379.SGD","LU0477156953.USD","LU1791807156.HKD","LU2361044949.HKD","LU0310799852.SGD","LU0683600562.USD","BK4218","LU0128525929.USD","IE0002270589.USD","LU1280957306.USD","BK4588","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU0742534661.SGD","LU0251131958.USD","LU0130517989.USD","LU2361045086.USD","LU0106831901.USD","LU0289960550.SGD","LU2361044865.SGD","LU0070302665.USD","LU0072461881.USD","LU0048573561.USD","LU1035773651.USD","LU0251142724.SGD","LU0130102774.USD"],"gpt_icon":0},{"id":"2512154076","title":"ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2512154076","media":"GlobeNewswire","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512154076?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883600,"startTime":"0","endTime":"0","summary":"Oral presentation on an efficacy study conducted in Japanese patients comparing anaphylaxis symptoms during oral food challenge with neffy as the initial treatment compared to site historical data on ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/18/3027762/0/en/ARS-Pharmaceuticals-to-Showcase-Innovation-and-Present-Data-on-neffy-epinephrine-nasal-spray-at-2025-American-Academy-of-Allergy-Asthma-and-Immunology-AAAAI-Annual-Scientific-Meeti.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","AFG","BK4218","LU1169590202.USD","BK4023","BK4181","BK4107","LU1169589451.USD","PD","BK4117"],"gpt_icon":0},{"id":"2512516545","title":"RANI: Impressive Bioavailability for RT-116","url":"https://stock-news.laohu8.com/highlight/detail?id=2512516545","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512516545?lang=en_us&edition=fundamental","pubTime":"2025-02-18 17:24","pubTimestamp":1739870640,"startTime":"0","endTime":"0","summary":"On February 5th, Rani Therapeutics Holdings, Inc.  shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of semaglutide using the RaniPill High Capacity  device compared to subcutaneous  injection. The study was conducted in eight canines to generate pharmacokinetic  and pharmacodynamic  data evaluating oral delivery of the glucagon-like peptide-1 receptor  agonist. In the press release, Rani updated stakeholders on the RT-114 program that is being developed with ProGen Co., targeting a start for the GLP-1/GLP-2 dual agonist Phase I study in 2025.A recent article in the Danish financial publication, Brsen, drew a connection between semaglutide’s sponsor, Novo Nordisk and Rani via a senior executive who previously served at the former and now acts as a Senior Strategic Advisor at the latter. The individual we are referring to is Jesper Hiland who highlighted several synergies between the RaniPill and future opportunities for the semaglutide brands O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rani-impressive-bioavailability-rt-116-092400369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","LU1169590202.USD","BK4023","RANI","LU1169589451.USD","PD","BK4218","BK4007","BK4539","BK4181"],"gpt_icon":0},{"id":"2512764749","title":"Park Hotels & Resorts Inc  expected to post earnings of 6 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2512764749","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512764749?lang=en_us&edition=fundamental","pubTime":"2025-02-18 05:58","pubTimestamp":1739829488,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts Inc  expected to post earnings of6cents a share - Earnings Preview Park Hotels & Resorts Inc PK.N, PK is expected to show a fall in quarterly revenue when it reports  results on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250217:nL5N3P81HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK"],"gpt_icon":0},{"id":"2512692947","title":"Park Hotels & Resorts (PK) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2512692947","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512692947?lang=en_us&edition=fundamental","pubTime":"2025-02-17 22:16","pubTimestamp":1739801769,"startTime":"0","endTime":"0","summary":"In its upcoming report, Park Hotels & Resorts  is predicted by Wall Street analysts to post quarterly earnings of $0.40 per share, reflecting a decline of 23.1% compared to the same period last year. Revenues are forecasted to be $603.98 million, representing a year-over-year decrease of 8.1%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.Analysts forecast 'Comparable RevPAR Growth' to reach -3.6%. The estimate compares to the year-ago value","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/park-hotels-resorts-pk-q4-141609711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK"],"gpt_icon":0},{"id":"2512950919","title":"Park Hotels & Resorts Inc. (PK): Among the Best Hotel Stocks to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2512950919","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512950919?lang=en_us&edition=fundamental","pubTime":"2025-02-17 06:03","pubTimestamp":1739743397,"startTime":"0","endTime":"0","summary":"We recently published a list of the 12 Best Hotel Stocks To Buy According to Analysts. In this article, we are going to take a look at where Park Hotels & Resorts Inc.  stands against other best hotel stocks to buy according to analysts.The hospitality industry is undergoing a significant transformation after the post-Covid travel rebound. According to a report by Zion Market Research, the global hotel market is valued at $1.37 trillion as of 2023. It is expected to reach $2.99 trillion by 2032, growing at a compound annual growth rate of 9.14% between 2024 and 2032. This growth is attributed to the surging travel demand post-Covid, resurgence in leisure and business activities, and increased disposable incomes.We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 hotel stocks. We checked their upside potential, according to analysts, and then selected the top 12 most popular stocks among elite hedge funds as of Q3 2024. We sourced the hedge fund sentimen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/park-hotels-resorts-inc-pk-220317521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","PK","BK4218"],"gpt_icon":0},{"id":"2511366259","title":"Press Release: Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2511366259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511366259?lang=en_us&edition=fundamental","pubTime":"2025-02-14 20:30","pubTimestamp":1739536200,"startTime":"0","endTime":"0","summary":"-- Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea. -- New OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms,\"Patients with obstructive sleep apnea need new and convenient therapeutic options to manage this serious, chronic and life-threatening disease. We are enthusiastic about the potential for IHL-42X, an oral, once-daily treatment that uniquely targets physiological pathways responsible for the airway obstruction characteristic of OSA. We achieved a key milestone for our OSA program, reporting positive top-line results from a pharmacokinetics  and safety study of IHL-42X, conducted alongside our global Phase 2/3 RePOSA study,\" said Joel Latham, Incannex's President and Chief Executive Officer. and safety study of IHL-42X, a novel, oral fixed-dose combination of","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","IH","BK4181","BK4218","HCSG","BK4510","AHI","BK4167","IXHL","RA","BK4007","BK4137","BK4085","PK","BK4097"],"gpt_icon":0},{"id":"2511911573","title":"Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2511911573","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511911573?lang=en_us&edition=fundamental","pubTime":"2025-02-14 01:45","pubTimestamp":1739468759,"startTime":"0","endTime":"0","summary":"Agios&#39; mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43704599/agios-pharmaceuticals-reveals-encouraging-data-from-rare-blood-disorder-study-in-younger-patients-aged-below-18-years","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4181","BK4218","BK4139","PK"],"gpt_icon":0},{"id":"2511322545","title":"Press Release: Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2511322545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511322545?lang=en_us&edition=fundamental","pubTime":"2025-02-13 19:31","pubTimestamp":1739446260,"startTime":"0","endTime":"0","summary":"-- Filed for Regulatory Approval of Mitapivat  for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 --. -- Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with Potential U.S. Commercial Launch in 2026 --. -- PYRUKYND Net Revenue of $10.7 Million in Q4; Cash, Cash Equivalents and Marketable Securities of $1.5 Billion as of December 31, 2024 --","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","BK4218","BK4139","BK4232","AGIO","PK","BK4181"],"gpt_icon":0},{"id":"2511194545","title":"Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2511194545","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511194545?lang=en_us&edition=fundamental","pubTime":"2025-02-13 19:30","pubTimestamp":1739446200,"startTime":"0","endTime":"0","summary":"– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –。– Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adults with PK Deficiency Who Are Not Regularly Transfused –。– First Mitapivat Pediatric Clinical Program for a Rare Hemolytic Anemia; Double-blind Period Completed for Both PK Deficiency Trials ACTIVATE-Kids and ACTIVATE-KidsT –。Topline results for the Phase 3 ACTIVATE-Kids trial were as follows:. The analysis of the primary endpoint was based on Bayesian statistical methodology whereby the hemoglobin response data from the adult ACTIVATE study inform and contribute to the analysis of hemoglobin response in the ACTIVATE-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-phase-3-activate-kids-113000487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGIO","BK4181","BK4218","BK4139","PK"],"gpt_icon":0},{"id":"2510371785","title":"Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2510371785","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510371785?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:00","pubTimestamp":1739365200,"startTime":"0","endTime":"0","summary":"Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder. SYDNEY, Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited  announces that the publication of its most recent peer-reviewed journal article entitled Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease in Clinical Pharmacology in Drug Development, the journal associated with the American College of Clinical Pharmacology.Actinogen Medical  is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.Actinogen is currently developing its lead compound, Xana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/actinogen-announces-peer-reviewed-clinical-130000077.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinogen-announces-peer-reviewed-clinical-130000077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7047","PD","BK4023","BK4218","BK4192","LU1169589451.USD","LU1169590202.USD","ACW.AU","PET","PET.AU","BK4181","BK7067","BK7508","PK"],"gpt_icon":0},{"id":"2510323373","title":"Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2510323373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510323373?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:00","pubTimestamp":1739361600,"startTime":"0","endTime":"0","summary":"TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AMLTUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patientsTUS+VEN+AZA triplet shows favor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/12/3024897/35575/en/Aptose-s-Frontline-Triple-Drug-Therapy-with-Tuspetinib-Achieves-Notable-Responses-in-Newly-Diagnosed-AML-Patients-in-the-Phase-1-2-TUSCANY-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","APTO","BK4139","BK4161","BK4218","PK","BK4181"],"gpt_icon":0},{"id":"2510155373","title":"Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2510155373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510155373?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:00","pubTimestamp":1739361600,"startTime":"0","endTime":"0","summary":"Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water submersionNew findings demonstrate dosing of Anap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/12/3024887/0/en/Aquestive-Therapeutics-to-Present-New-Findings-on-Anaphylm-Epinephrine-Sublingual-Film-at-the-2025-AAAAI-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4181","BK4139","BK4218","LU1169589451.USD","LU1169590202.USD","AQST","BK4023","BK4007","LENZ","PD"],"gpt_icon":0},{"id":"2510534373","title":"New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3","url":"https://stock-news.laohu8.com/highlight/detail?id=2510534373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510534373?lang=en_us&edition=fundamental","pubTime":"2025-02-12 19:50","pubTimestamp":1739361000,"startTime":"0","endTime":"0","summary":"- Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb.  12, 2025  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/12/3024875/37216/en/New-Publication-Highlights-Unique-Properties-of-ATI-2138-a-Potent-and-Selective-Inhibitor-of-ITK-and-JAK3.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","BK4023","BK4006","ATI","PD","BK4218","LU1169589451.USD","LU1169590202.USD","IE0031619046.USD","ACRS","BK4181","IE00B19Z4B17.USD","LU1878469433.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","PK","BK4007"],"gpt_icon":0},{"id":"2510571238","title":"Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2510571238","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510571238?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:45","pubTimestamp":1739195100,"startTime":"0","endTime":"0","summary":"Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure  Company","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/10/3023457/0/en/Palisade-Bio-Presents-Positive-Preclinical-Data-of-PALI-2108-for-the-Treatment-of-Ulcerative-Colitis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4139","PALI","BK4007","BK4181","PK"],"gpt_icon":1},{"id":"2510880381","title":"Zacks Market Edge Highlights: WASH, SPG PAA, PK and ETD","url":"https://stock-news.laohu8.com/highlight/detail?id=2510880381","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510880381?lang=en_us&edition=fundamental","pubTime":"2025-02-10 14:21","pubTimestamp":1739168460,"startTime":"0","endTime":"0","summary":"Welcome to Episode #433 of the Zacks Market Edge Podcast. - Finding Strong Income Stocks For Your Portfolio Right Now.  - Tracey's Top Stock Picks For Your Watchlist.  - Episode Roundup: WASH, SPG, PAA, AK, ETD. Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds, and ETFs and how it impacts your life.This week, Tracey is going solo to look at the top ranked Zacks Stocks of #1  and #2 , which also pay big dividends.Washington Trust is a Zacks #2  stock. The Zacks Consensus Estimate has 2025 earnings rising 13.9%. Washington Trust is paying a big dividend, well over 4%.Earnings of Plains All American Pipeline are expected to rise 9.9% in 2024 but fall 6% in 2025. But Plains All American Pipeline still has the coveted Zacks #1  rank. It pays a dividend yielding 7.5%.Should those looking for stable income consider an MLP like Plains All American Pipeline?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-market-edge-highlights-wash-062100255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4590","WASH","BK4231","BK4181","BK4095","BK4144","BK4218","ETD","PAA","BK4211","BK4080","BK4585","BK4588","SPG"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PK\",params:#limit:5,,,undefined,":[{"date":"2025-05-05","symbol":"PK","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.39,"defaultRemindTime":1746432000000,"name":null,"time":"Pre-Market","dateTimestamp":1746417600000,"actualEps":null},{"date":"2025-03-31","symbol":"PK","amount":0.25,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-15","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-15"},{"date":"2025-02-19","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":0.37,"defaultRemindTime":1739998800000,"name":null,"time":"Post Market","dateTimestamp":1739941200000,"actualEps":null},{"date":"2024-12-31","symbol":"PK","amount":0.65,"announcedDate":"2024-11-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-31","defaultRemindTime":1735655400000,"name":"Park Hotels & Resorts Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-15","payableDate":"2024-12-31","currency":"USD","dateTimestamp":1735621200000,"payDate":"2025-01-15"},{"date":"2024-10-29","symbol":"PK","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/09","expectedEps":0.47,"defaultRemindTime":1730232000000,"name":null,"time":"Post Market","dateTimestamp":1730174400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PK\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-17","value":0.43,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-17","value":0.43,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-16","value":0.43,"currency":"USD"},{"executeDate":"2017-12-28","recordDate":"2017-12-29","paymentDate":"2018-01-16","value":0.55,"currency":"USD"},{"executeDate":"2018-03-28","recordDate":"2018-03-30","paymentDate":"2018-04-16","value":0.43,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PK\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.25,"hold":0.625,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":16,"updateTime":1744257600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PK\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PK","date":"2025-04-24","current":9.417154,"percent":0.686935,"low":-68.24471,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"high":55.399897,"avg":-2.80083,"sd":27.197354,"marketCap":1996436690},"quantilePoints":[{"date":"2020-05-01","current":6.781686,"twenty":11.855583,"median":14.661134,"eighty":31.814372,"marketCap":2075195859},{"date":"2020-05-08","current":6.844479,"twenty":11.80177,"median":14.646936,"eighty":31.785807,"marketCap":2094410636},{"date":"2020-05-15","current":-3.602916,"twenty":11.684678,"median":14.629627,"eighty":31.749191,"marketCap":1722193974},{"date":"2020-05-22","current":-4.628096,"twenty":11.308585,"median":14.609077,"eighty":31.647673,"marketCap":2212230016},{"date":"2020-05-29","current":-4.844961,"twenty":11.239782,"median":14.592668,"eighty":31.498937,"marketCap":2315891487},{"date":"2020-06-05","current":-6.446805,"twenty":11.167874,"median":14.571217,"eighty":31.464863,"marketCap":3081572803},{"date":"2020-06-12","current":-5.712421,"twenty":11.131908,"median":14.542822,"eighty":31.43819,"marketCap":2730537369},{"date":"2020-06-19","current":-5.278691,"twenty":11.055905,"median":14.514879,"eighty":31.414917,"marketCap":2523214428},{"date":"2020-06-26","current":-4.682313,"twenty":10.886453,"median":14.495498,"eighty":31.375334,"marketCap":2238145384},{"date":"2020-07-02","current":-4.746386,"twenty":10.800505,"median":14.4813,"eighty":31.352562,"marketCap":2268772637},{"date":"2020-07-10","current":-4.756244,"twenty":10.682725,"median":14.429243,"eighty":31.344509,"marketCap":2273484522},{"date":"2020-07-17","current":-4.514735,"twenty":7.464564,"median":14.377186,"eighty":31.340758,"marketCap":2158043339},{"date":"2020-07-24","current":-4.204224,"twenty":6.899423,"median":14.324128,"eighty":31.317149,"marketCap":2009618961},{"date":"2020-07-31","current":-4.076076,"twenty":6.656099,"median":14.175607,"eighty":31.295818,"marketCap":1948364455},{"date":"2020-08-07","current":-2.566048,"twenty":6.428473,"median":14.137595,"eighty":31.259301,"marketCap":2101593620},{"date":"2020-08-14","current":-2.721392,"twenty":6.26364,"median":14.089266,"eighty":31.247128,"marketCap":2228820140},{"date":"2020-08-21","current":-2.525774,"twenty":6.153752,"median":14.006744,"eighty":31.247128,"marketCap":2068608967},{"date":"2020-08-28","current":-2.870982,"twenty":5.863333,"median":13.870814,"eighty":31.210909,"marketCap":2351334566},{"date":"2020-09-04","current":-3.046463,"twenty":5.667103,"median":13.801033,"eighty":31.128278,"marketCap":2495053412},{"date":"2020-09-11","current":-2.902626,"twenty":5.384533,"median":13.774657,"eighty":31.118835,"marketCap":2377251079},{"date":"2020-09-18","current":-3.095368,"twenty":4.792705,"median":13.714879,"eighty":31.059812,"marketCap":2535106206},{"date":"2020-09-25","current":-2.819201,"twenty":2.477694,"median":13.678818,"eighty":30.998429,"marketCap":2308925726},{"date":"2020-10-02","current":-3.046463,"twenty":2.452731,"median":13.647472,"eighty":30.967738,"marketCap":2495053412},{"date":"2020-10-09","current":-3.103998,"twenty":2.419945,"median":13.625211,"eighty":30.925242,"marketCap":2542174346},{"date":"2020-10-16","current":-2.865229,"twenty":2.407631,"median":13.604071,"eighty":30.830806,"marketCap":2346622473},{"date":"2020-10-23","current":-3.106875,"twenty":2.39881,"median":13.60157,"eighty":30.809558,"marketCap":2544530392},{"date":"2020-10-30","current":-2.856599,"twenty":2.384831,"median":13.570144,"eighty":30.743453,"marketCap":2339554333},{"date":"2020-11-06","current":-2.206192,"twenty":2.293797,"median":13.511461,"eighty":30.717484,"marketCap":2426811706},{"date":"2020-11-13","current":-3.043689,"twenty":2.260846,"median":13.488575,"eighty":30.70568,"marketCap":3348057703},{"date":"2020-11-20","current":-3.221469,"twenty":2.22504,"median":13.471041,"eighty":30.674988,"marketCap":3543616316},{"date":"2020-11-27","current":-3.581314,"twenty":2.209754,"median":13.450169,"eighty":30.667905,"marketCap":3939445798},{"date":"2020-12-04","current":-3.885469,"twenty":2.206595,"median":13.437336,"eighty":30.660823,"marketCap":4274015956},{"date":"2020-12-11","current":-3.77623,"twenty":2.197164,"median":13.4098,"eighty":30.634853,"marketCap":4153853434},{"date":"2020-12-18","current":-3.649856,"twenty":2.188516,"median":13.398907,"eighty":30.606523,"marketCap":4014841890},{"date":"2020-12-24","current":-3.681985,"twenty":2.181468,"median":13.390367,"eighty":30.587635,"marketCap":4050183808},{"date":"2020-12-31","current":-3.673418,"twenty":2.165633,"median":13.373288,"eighty":30.559305,"marketCap":4040759297},{"date":"2021-01-08","current":-3.726966,"twenty":2.127386,"median":13.357167,"eighty":30.487456,"marketCap":4099662493},{"date":"2021-01-15","current":-3.711972,"twenty":2.090996,"median":13.34366,"eighty":30.406499,"marketCap":4083169598},{"date":"2021-01-22","current":-3.889753,"twenty":2.071846,"median":13.334859,"eighty":30.325661,"marketCap":4278728211},{"date":"2021-01-29","current":-3.572747,"twenty":2.068781,"median":13.320798,"eighty":30.089882,"marketCap":3930021287},{"date":"2021-02-05","current":-3.887611,"twenty":2.05882,"median":13.314589,"eighty":29.899013,"marketCap":4276372084},{"date":"2021-02-12","current":-4.215327,"twenty":2.034301,"median":13.288201,"eighty":29.854103,"marketCap":4636859648},{"date":"2021-02-19","current":-4.444514,"twenty":2.013845,"median":13.280132,"eighty":29.737337,"marketCap":4888965330},{"date":"2021-02-26","current":-3.563311,"twenty":-2.231897,"median":13.271323,"eighty":29.699163,"marketCap":5131167540},{"date":"2021-03-05","current":-3.448497,"twenty":-2.455006,"median":13.256856,"eighty":29.625061,"marketCap":4965836198},{"date":"2021-03-12","current":-3.740659,"twenty":-2.561446,"median":13.245191,"eighty":29.508294,"marketCap":5386549593},{"date":"2021-03-19","current":-3.755425,"twenty":-2.654652,"median":13.226158,"eighty":29.474611,"marketCap":5407812650},{"date":"2021-03-26","current":-3.589648,"twenty":-2.723118,"median":13.200933,"eighty":29.409492,"marketCap":5169093647},{"date":"2021-04-01","current":-3.581442,"twenty":-2.747858,"median":13.188305,"eighty":29.387036,"marketCap":5157275875},{"date":"2021-04-09","current":-3.522353,"twenty":-2.785256,"median":13.150762,"eighty":29.281497,"marketCap":5072187914},{"date":"2021-04-16","current":-3.497732,"twenty":-2.84164,"median":13.078426,"eighty":29.200659,"marketCap":5036734596},{"date":"2021-04-23","current":-3.597855,"twenty":-2.856599,"median":13.071715,"eighty":29.043473,"marketCap":5180911420},{"date":"2021-04-30","current":-3.661868,"twenty":-2.86063,"median":13.065856,"eighty":28.92446,"marketCap":5273090044},{"date":"2021-05-07","current":-5.611001,"twenty":-2.872133,"median":13.00038,"eighty":27.600316,"marketCap":5285562943},{"date":"2021-05-14","current":-5.538196,"twenty":-2.918736,"median":12.98625,"eighty":26.702293,"marketCap":5216980694},{"date":"2021-05-21","current":-5.07124,"twenty":-2.973394,"median":12.984113,"eighty":26.504319,"marketCap":4777108342},{"date":"2021-05-28","current":-5.219361,"twenty":-3.010216,"median":12.953043,"eighty":26.370989,"marketCap":4916637744},{"date":"2021-06-04","current":-5.151577,"twenty":-3.032655,"median":12.935438,"eighty":26.342707,"marketCap":4852785306},{"date":"2021-06-11","current":-5.407649,"twenty":-3.066646,"median":12.921003,"eighty":26.23968,"marketCap":5094005628},{"date":"2021-06-18","current":-5.181703,"twenty":-3.103007,"median":12.910479,"eighty":26.122512,"marketCap":4881164167},{"date":"2021-06-25","current":-5.407649,"twenty":-3.130464,"median":12.883118,"eighty":26.110391,"marketCap":5094005628},{"date":"2021-07-02","current":-5.103877,"twenty":-3.201231,"median":12.837305,"eighty":26.041706,"marketCap":4807852108},{"date":"2021-07-09","current":-4.933162,"twenty":-3.220989,"median":12.808486,"eighty":25.863933,"marketCap":4647038560},{"date":"2021-07-16","current":-4.616837,"twenty":-3.39668,"median":12.795175,"eighty":25.55283,"marketCap":4349060515},{"date":"2021-07-23","current":-4.684621,"twenty":-3.442298,"median":12.778454,"eighty":25.461924,"marketCap":4412912953},{"date":"2021-07-30","current":-4.644453,"twenty":-3.472857,"median":12.762007,"eighty":25.27203,"marketCap":4375074472},{"date":"2021-08-06","current":-5.555659,"twenty":-3.499046,"median":12.754728,"eighty":25.175063,"marketCap":4438971639},{"date":"2021-08-13","current":-5.472783,"twenty":-3.515459,"median":12.739067,"eighty":25.092237,"marketCap":4372753628},{"date":"2021-08-20","current":-5.209355,"twenty":-3.540249,"median":12.712634,"eighty":25.013451,"marketCap":4162274952},{"date":"2021-08-27","current":-5.74509,"twenty":-3.546559,"median":12.705805,"eighty":24.987189,"marketCap":4590327091},{"date":"2021-09-03","current":-5.52902,"twenty":-3.565932,"median":12.702277,"eighty":24.944766,"marketCap":4417687278},{"date":"2021-09-10","current":-5.437265,"twenty":-3.571599,"median":12.695796,"eighty":24.807396,"marketCap":4344374481},{"date":"2021-09-17","current":-5.688853,"twenty":-3.581314,"median":12.675381,"eighty":24.746792,"marketCap":4545393441},{"date":"2021-09-24","current":-5.97004,"twenty":-3.589648,"median":12.636863,"eighty":24.72659,"marketCap":4770061692},{"date":"2021-10-01","current":-5.896043,"twenty":-3.599497,"median":12.622139,"eighty":24.665986,"marketCap":4710938468},{"date":"2021-10-08","current":-5.721411,"twenty":-3.607845,"median":12.595518,"eighty":24.655885,"marketCap":4571407660},{"date":"2021-10-15","current":-5.659254,"twenty":-3.625758,"median":12.578404,"eighty":24.655885,"marketCap":4521744152},{"date":"2021-10-22","current":-5.505341,"twenty":-3.649856,"median":12.569511,"eighty":24.645785,"marketCap":4398767847},{"date":"2021-10-29","current":-5.484622,"twenty":-3.670075,"median":12.545167,"eighty":24.625583,"marketCap":4382213344},{"date":"2021-11-05","current":-8.201051,"twenty":-3.681985,"median":12.518997,"eighty":24.605382,"marketCap":4994440260},{"date":"2021-11-12","current":-7.56811,"twenty":-3.701263,"median":12.505104,"eighty":24.575079,"marketCap":4608979198},{"date":"2021-11-19","current":-7.339009,"twenty":-3.720957,"median":12.481428,"eighty":24.44377,"marketCap":4469456483},{"date":"2021-11-26","current":-6.989532,"twenty":-3.729965,"median":12.465978,"eighty":24.427609,"marketCap":4256625222},{"date":"2021-12-03","current":-6.488616,"twenty":-3.750955,"median":12.411262,"eighty":24.415488,"marketCap":3951567081},{"date":"2021-12-10","current":-7.129323,"twenty":-3.770233,"median":12.390156,"eighty":24.397368,"marketCap":4341757726},{"date":"2021-12-17","current":-6.752665,"twenty":-3.792938,"median":12.369502,"eighty":24.247831,"marketCap":4112372922},{"date":"2021-12-23","current":-7.490449,"twenty":-3.83227,"median":12.348324,"eighty":24.162969,"marketCap":4561683362},{"date":"2021-12-31","current":-7.331243,"twenty":-3.873903,"median":12.336915,"eighty":24.124587,"marketCap":4464726899},{"date":"2022-01-07","current":-7.692369,"twenty":-3.888468,"median":12.314228,"eighty":24.072063,"marketCap":4684652535},{"date":"2022-01-14","current":-7.548695,"twenty":-3.917478,"median":12.283673,"eighty":24.03368,"marketCap":4597155239},{"date":"2022-01-21","current":-7.032246,"twenty":-3.996222,"median":12.241172,"eighty":24.02964,"marketCap":4282637931},{"date":"2022-01-28","current":-6.803145,"twenty":-4.087905,"median":12.214275,"eighty":24.013479,"marketCap":4143115216},{"date":"2022-02-04","current":-7.051662,"twenty":-4.210886,"median":12.177189,"eighty":23.964995,"marketCap":4294461890},{"date":"2022-02-11","current":-7.339009,"twenty":-4.305038,"median":12.115818,"eighty":23.924593,"marketCap":4469456483},{"date":"2022-02-18","current":-9.97933,"twenty":-4.379327,"median":12.077002,"eighty":23.906411,"marketCap":4580512556},{"date":"2022-02-25","current":-9.762948,"twenty":-4.434604,"median":12.034907,"eighty":23.88419,"marketCap":4481193234},{"date":"2022-03-04","current":-9.294121,"twenty":-4.477502,"median":11.989722,"eighty":23.857928,"marketCap":4266001369},{"date":"2022-03-11","current":-9.515655,"twenty":-4.530065,"median":11.874947,"eighty":23.585208,"marketCap":4367685437},{"date":"2022-03-18","current":-9.793479,"twenty":-4.62021,"median":11.802039,"eighty":23.304408,"marketCap":4495206674},{"date":"2022-03-25","current":-9.839796,"twenty":-4.668569,"median":11.613959,"eighty":23.136735,"marketCap":4516466191},{"date":"2022-04-01","current":-10.045649,"twenty":-4.723283,"median":11.244693,"eighty":22.801391,"marketCap":4610952931},{"date":"2022-04-08","current":-8.795089,"twenty":-4.748358,"median":11.177001,"eighty":22.577155,"marketCap":4036945983},{"date":"2022-04-14","current":-9.860381,"twenty":-4.774334,"median":11.132722,"eighty":22.280194,"marketCap":4525914865},{"date":"2022-04-22","current":-9.999332,"twenty":-4.831692,"median":11.002063,"eighty":21.938028,"marketCap":4589693414},{"date":"2022-04-29","current":-10.143429,"twenty":-4.933265,"median":10.846102,"eighty":20.988446,"marketCap":4655834133},{"date":"2022-05-06","current":-13.808923,"twenty":-5.010567,"median":10.72108,"eighty":20.329014,"marketCap":4501708843},{"date":"2022-05-13","current":-13.178967,"twenty":-5.093895,"median":7.386072,"eighty":20.146479,"marketCap":4296343172},{"date":"2022-05-20","current":-11.861786,"twenty":-5.147058,"median":6.828781,"eighty":19.994366,"marketCap":3866942225},{"date":"2022-05-27","current":-13.143174,"twenty":-5.175677,"median":6.45202,"eighty":19.781409,"marketCap":4284674668},{"date":"2022-06-03","current":-13.207601,"twenty":-5.20439,"median":6.373529,"eighty":19.661408,"marketCap":4305677976},{"date":"2022-06-10","current":-12.055068,"twenty":-5.217352,"median":6.1773,"eighty":18.57907,"marketCap":3929952147},{"date":"2022-06-17","current":-10.229627,"twenty":-5.287145,"median":5.839785,"eighty":18.013987,"marketCap":3334858443},{"date":"2022-06-24","current":-10.1652,"twenty":-5.323251,"median":5.651405,"eighty":17.603643,"marketCap":3313855136},{"date":"2022-07-01","current":-9.70705,"twenty":-5.360954,"median":5.101963,"eighty":17.208917,"marketCap":3164498284},{"date":"2022-07-08","current":-9.85738,"twenty":-5.388567,"median":3.861793,"eighty":17.068349,"marketCap":3213506001},{"date":"2022-07-15","current":-9.921808,"twenty":-5.409668,"median":2.45556,"eighty":16.809931,"marketCap":3234509308},{"date":"2022-07-22","current":-10.487336,"twenty":-5.439477,"median":2.417283,"eighty":16.594109,"marketCap":3418871672},{"date":"2022-07-29","current":-11.160244,"twenty":-5.472783,"median":2.404801,"eighty":15.354106,"marketCap":3638239547},{"date":"2022-08-05","current":-56.398031,"twenty":-5.505341,"median":2.387327,"eighty":15.148576,"marketCap":3383881882},{"date":"2022-08-12","current":-60.145409,"twenty":-5.52902,"median":2.299955,"eighty":15.006602,"marketCap":3608724532},{"date":"2022-08-19","current":-55.873399,"twenty":-5.552107,"median":2.257518,"eighty":14.887345,"marketCap":3352403911},{"date":"2022-08-26","current":-53.287708,"twenty":-5.563474,"median":2.212781,"eighty":14.845845,"marketCap":3197262483},{"date":"2022-09-02","current":-52.238442,"twenty":-5.614856,"median":2.207821,"eighty":14.818112,"marketCap":3134306541},{"date":"2022-09-09","current":-54.786659,"twenty":-5.644455,"median":2.197209,"eighty":14.800268,"marketCap":3287199543},{"date":"2022-09-16","current":-52.051073,"twenty":-5.663398,"median":2.187137,"eighty":14.752289,"marketCap":3123064408},{"date":"2022-09-23","current":-44.593792,"twenty":-5.688853,"median":2.168482,"eighty":14.705619,"marketCap":2675627535},{"date":"2022-09-30","current":-42.195471,"twenty":-5.714833,"median":2.125089,"eighty":14.651669,"marketCap":2531728239},{"date":"2022-10-07","current":-43.582,"twenty":-5.729107,"median":2.082185,"eighty":14.616649,"marketCap":2614920019},{"date":"2022-10-14","current":-44.219054,"twenty":-5.777649,"median":2.070313,"eighty":14.587307,"marketCap":2653143270},{"date":"2022-10-21","current":-47.216957,"twenty":-5.925642,"median":2.05882,"eighty":14.530184,"marketCap":2833017390},{"date":"2022-10-28","current":-48.828329,"twenty":-6.246611,"median":2.029326,"eighty":14.486979,"marketCap":2929699729},{"date":"2022-11-04","current":43.862859,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2675634425},{"date":"2022-11-11","current":47.03278,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2868999602},{"date":"2022-11-18","current":45.005505,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2745335826},{"date":"2022-11-25","current":45.742696,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2790304471},{"date":"2022-12-02","current":46.553606,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2839769982},{"date":"2022-12-09","current":45.41096,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2770068581},{"date":"2022-12-16","current":44.342034,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2704864044},{"date":"2022-12-23","current":42.941371,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2619423617},{"date":"2022-12-30","current":43.457404,"twenty":-6.452657,"median":2.015912,"eighty":14.434922,"marketCap":2650901669},{"date":"2023-01-06","current":44.010298,"twenty":-6.452657,"median":2.015912,"eighty":14.499284,"marketCap":2684628154},{"date":"2023-01-13","current":46.332449,"twenty":-6.452657,"median":2.015912,"eighty":14.544715,"marketCap":2826279388},{"date":"2023-01-20","current":47.585674,"twenty":-6.452657,"median":2.015912,"eighty":14.591155,"marketCap":2902726086},{"date":"2023-01-27","current":53.188324,"twenty":-6.452657,"median":2.015912,"eighty":14.629303,"marketCap":3244487794},{"date":"2023-02-03","current":54.478409,"twenty":-6.452657,"median":2.015912,"eighty":14.659241,"marketCap":3323182924},{"date":"2023-02-10","current":52.598572,"twenty":-6.452657,"median":2.015912,"eighty":14.710351,"marketCap":3208512877},{"date":"2023-02-17","current":50.681875,"twenty":-6.452657,"median":2.015912,"eighty":14.776825,"marketCap":3091594398},{"date":"2023-02-24","current":19.081678,"twenty":-6.452657,"median":2.015912,"eighty":14.800268,"marketCap":3091231855},{"date":"2023-03-03","current":19.2873,"twenty":-6.452657,"median":2.020509,"eighty":14.820409,"marketCap":3124542543},{"date":"2023-03-10","current":17.080295,"twenty":-6.452657,"median":2.020509,"eighty":14.858004,"marketCap":2767007824},{"date":"2023-03-17","current":15.80726,"twenty":-6.452657,"median":2.020509,"eighty":14.898703,"marketCap":2560776060},{"date":"2023-03-24","current":15.423721,"twenty":-6.452657,"median":2.034301,"eighty":15.020423,"marketCap":2498642845},{"date":"2023-03-31","current":16.930479,"twenty":-6.449731,"median":2.061884,"eighty":15.148576,"marketCap":2742737617},{"date":"2023-04-06","current":16.355172,"twenty":-6.449731,"median":2.08027,"eighty":15.339767,"marketCap":2649537795},{"date":"2023-04-14","current":16.231891,"twenty":-6.452657,"median":2.187137,"eighty":15.656584,"marketCap":2629566405},{"date":"2023-04-21","current":16.1771,"twenty":-6.452657,"median":2.20399,"eighty":16.160663,"marketCap":2620690231},{"date":"2023-04-28","current":15.916842,"twenty":-6.452657,"median":3.861793,"eighty":16.193538,"marketCap":2578528407},{"date":"2023-05-05","current":10.781494,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2716936387},{"date":"2023-05-12","current":11.431806,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2880815089},{"date":"2023-05-19","current":11.705622,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2949816648},{"date":"2023-05-26","current":11.13232,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2805344634},{"date":"2023-06-02","current":11.115206,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2801032037},{"date":"2023-06-09","current":12.184799,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":3070569377},{"date":"2023-06-16","current":11.243558,"twenty":-6.452657,"median":4.795845,"eighty":16.193538,"marketCap":2833376518},{"date":"2023-06-23","current":10.71304,"twenty":-6.455582,"median":4.787996,"eighty":16.201756,"marketCap":2699685997},{"date":"2023-06-30","current":10.926958,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2753593465},{"date":"2023-07-07","current":11.226444,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2829063920},{"date":"2023-07-14","current":11.799746,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2973535934},{"date":"2023-07-21","current":11.260671,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2837689115},{"date":"2023-07-28","current":10.76438,"twenty":-6.458508,"median":4.780147,"eighty":16.209975,"marketCap":2712623789},{"date":"2023-08-04","current":-57.485197,"twenty":-6.501042,"median":3.861793,"eighty":16.209975,"marketCap":2759289480},{"date":"2023-08-11","current":-60.090736,"twenty":-6.750335,"median":-2.450979,"eighty":16.209975,"marketCap":2884355344},{"date":"2023-08-18","current":-56.854736,"twenty":-6.930509,"median":-2.566048,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-25","current":-56.854736,"twenty":-7.00324,"median":-2.678241,"eighty":16.209975,"marketCap":2729027307},{"date":"2023-08-31","current":-58.203069,"twenty":-7.047778,"median":-2.730022,"eighty":16.209975,"marketCap":2793747322},{"date":"2023-09-08","current":-56.225513,"twenty":-7.135536,"median":-2.76742,"eighty":16.220933,"marketCap":2698824633},{"date":"2023-09-13","current":-59.641292,"twenty":-7.238826,"median":-2.81236,"eighty":16.220933,"marketCap":2862782005},{"date":"2023-09-20","current":-56.49518,"twenty":-7.292412,"median":-2.856599,"eighty":16.226412,"marketCap":2711768636},{"date":"2023-09-29","current":-56.270458,"twenty":-7.33179,"median":-2.859478,"eighty":16.256547,"marketCap":2700981967},{"date":"2023-10-06","current":-54.068179,"twenty":-7.350658,"median":-2.872421,"eighty":16.256547,"marketCap":2595272609},{"date":"2023-10-13","current":-54.023235,"twenty":-7.41434,"median":-2.928517,"eighty":16.256547,"marketCap":2593115275},{"date":"2023-10-20","current":-52.944568,"twenty":-7.474917,"median":-3.004751,"eighty":16.256547,"marketCap":2541339263},{"date":"2023-10-23","current":-52.405235,"twenty":-7.491226,"median":-3.007627,"eighty":16.256547,"marketCap":2515451257},{"date":"2023-11-03","current":-48.333767,"twenty":-7.537046,"median":-3.046463,"eighty":16.355172,"marketCap":2706690937},{"date":"2023-11-10","current":-48.821216,"twenty":-7.614707,"median":-3.102759,"eighty":16.355172,"marketCap":2733988086},{"date":"2023-11-17","current":-52.758411,"twenty":-7.692369,"median":-3.147149,"eighty":16.355172,"marketCap":2954470996},{"date":"2023-11-24","current":-54.558271,"twenty":-8.07291,"median":-3.21274,"eighty":16.355172,"marketCap":3055263184},{"date":"2023-12-01","current":-55.60819,"twenty":-8.887723,"median":-3.353198,"eighty":16.355172,"marketCap":3114058626},{"date":"2023-12-08","current":-56.170646,"twenty":-9.20165,"median":-3.416563,"eighty":16.355172,"marketCap":3145556185},{"date":"2023-12-13","current":-57.820518,"twenty":-9.294121,"median":-3.460856,"eighty":16.355172,"marketCap":3237949024},{"date":"2023-12-22","current":-62.432661,"twenty":-9.507389,"median":-3.497732,"eighty":16.36339,"marketCap":3496229004},{"date":"2024-01-05","current":-59.020425,"twenty":-9.574387,"median":-3.519891,"eighty":16.393525,"marketCap":3305143815},{"date":"2024-01-12","current":-60.445315,"twenty":-9.664756,"median":-3.542049,"eighty":16.393525,"marketCap":3384937630},{"date":"2024-01-19","current":-59.99535,"twenty":-9.712777,"median":-3.553469,"eighty":16.401744,"marketCap":3359739584},{"date":"2024-01-26","current":-58.232986,"twenty":-9.763771,"median":-3.571596,"eighty":16.393525,"marketCap":3261047233},{"date":"2024-02-02","current":-66.888565,"twenty":-9.823019,"median":-3.581378,"eighty":16.393525,"marketCap":3210651139},{"date":"2024-02-09","current":-57.220565,"twenty":-9.869644,"median":-3.59147,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-16","current":-57.220565,"twenty":-9.956321,"median":-3.604489,"eighty":16.393525,"marketCap":3204351628},{"date":"2024-02-23","current":-60.89528,"twenty":-10.043591,"median":-3.622011,"eighty":16.393525,"marketCap":3410135677},{"date":"2024-03-01","current":35.936019,"twenty":-10.056469,"median":-3.625758,"eighty":16.447807,"marketCap":3485793844},{"date":"2024-03-08","current":37.18843,"twenty":-10.056469,"median":-3.625758,"eighty":16.567212,"marketCap":3607277745},{"date":"2024-03-15","current":36.961243,"twenty":-10.056469,"median":-3.625758,"eighty":16.670221,"marketCap":3585240545},{"date":"2024-03-22","current":38.523902,"twenty":-10.056469,"median":-3.625758,"eighty":16.766106,"marketCap":3736818537},{"date":"2024-03-28","current":38.306866,"twenty":-10.056469,"median":-3.625758,"eighty":16.809931,"marketCap":3715766038},{"date":"2024-04-05","current":37.156575,"twenty":-10.059306,"median":-3.629041,"eighty":16.978896,"marketCap":3604187794},{"date":"2024-04-12","current":37.894498,"twenty":-10.059306,"median":-3.629041,"eighty":17.16064,"marketCap":3675766290},{"date":"2024-04-19","current":35.007918,"twenty":-10.059306,"median":-3.629041,"eighty":17.258612,"marketCap":3395768056},{"date":"2024-04-26","current":35.44199,"twenty":-10.056469,"median":-3.625758,"eighty":17.840762,"marketCap":3437873054},{"date":"2024-05-03","current":36.498796,"twenty":-10.056469,"median":-3.625758,"eighty":18.170174,"marketCap":3357889189},{"date":"2024-05-10","current":36.511207,"twenty":-10.056469,"median":-3.625758,"eighty":18.755351,"marketCap":3359031034},{"date":"2024-05-17","current":37.541304,"twenty":-10.056469,"median":-3.625758,"eighty":19.13678,"marketCap":3453799934},{"date":"2024-05-24","current":36.396752,"twenty":-10.056469,"median":-3.625758,"eighty":19.228198,"marketCap":3348501156},{"date":"2024-05-31","current":35.595565,"twenty":-10.056469,"median":-3.625758,"eighty":19.551549,"marketCap":3274792011},{"date":"2024-06-07","current":34.863052,"twenty":-10.056469,"median":-3.625758,"eighty":19.788169,"marketCap":3207400793},{"date":"2024-06-14","current":34.496795,"twenty":-10.059306,"median":-3.629041,"eighty":19.972394,"marketCap":3173705183},{"date":"2024-06-21","current":33.832955,"twenty":-10.062143,"median":-3.632324,"eighty":20.117746,"marketCap":3112631892},{"date":"2024-06-28","current":34.061866,"twenty":-10.071657,"median":-3.634664,"eighty":20.170141,"marketCap":3133691648},{"date":"2024-07-05","current":33.398026,"twenty":-10.071657,"median":-3.634664,"eighty":20.359437,"marketCap":3072618356},{"date":"2024-07-12","current":32.779968,"twenty":-10.071657,"median":-3.634664,"eighty":20.997672,"marketCap":3015757016},{"date":"2024-07-15","current":33.466699,"twenty":-10.071657,"median":-3.634664,"eighty":21.055774,"marketCap":3078936283},{"date":"2024-08-02","current":10.070358,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3081529526},{"date":"2024-08-09","current":9.455895,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2893503995},{"date":"2024-08-16","current":9.763127,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2987516760},{"date":"2024-08-23","current":10.179596,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3114956286},{"date":"2024-08-30","current":10.309316,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":3154650565},{"date":"2024-09-06","current":9.742645,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2981249243},{"date":"2024-09-13","current":9.408104,"twenty":-10.150883,"median":-3.673418,"eighty":21.36338,"marketCap":2878879787},{"date":"2024-09-20","current":10.718957,"twenty":-10.150883,"median":-3.673418,"eighty":21.101408,"marketCap":3280000919},{"date":"2024-09-27","current":10.084013,"twenty":-10.150883,"median":-3.673418,"eighty":20.560563,"marketCap":3085707871},{"date":"2024-10-04","current":9.585615,"twenty":-10.150883,"median":-3.673418,"eighty":20.205634,"marketCap":2933198274},{"date":"2024-10-11","current":9.756299,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2985427588},{"date":"2024-10-18","current":9.626579,"twenty":-10.150883,"median":-3.673418,"eighty":20.146479,"marketCap":2945733309},{"date":"2024-10-25","current":9.462723,"twenty":-10.150883,"median":-3.673418,"eighty":20.138028,"marketCap":2895593168},{"date":"2024-10-31","current":8.714822,"twenty":-10.150883,"median":-3.673418,"eighty":19.647887,"marketCap":2902035670},{"date":"2024-11-08","current":9.117754,"twenty":-10.153746,"median":-3.674208,"eighty":19.166669,"marketCap":3036211945},{"date":"2024-11-15","current":9.111555,"twenty":-10.153746,"median":-3.674208,"eighty":18.78122,"marketCap":3034147899},{"date":"2024-11-22","current":9.099159,"twenty":-10.153746,"median":-3.674208,"eighty":16.930479,"marketCap":3030019806},{"date":"2024-11-29","current":9.638414,"twenty":-10.153746,"median":-3.674208,"eighty":16.766106,"marketCap":3209591825},{"date":"2024-12-06","current":9.756182,"twenty":-10.153746,"median":-3.674208,"eighty":16.574337,"marketCap":3248808703},{"date":"2024-12-13","current":9.53924,"twenty":-10.153746,"median":-3.674208,"eighty":16.377088,"marketCap":3176567086},{"date":"2024-12-20","current":8.968994,"twenty":-10.153746,"median":-3.674208,"eighty":16.1771,"marketCap":2986674836},{"date":"2024-12-27","current":9.334695,"twenty":-10.153746,"median":-3.674208,"eighty":15.960675,"marketCap":3108453562},{"date":"2025-01-03","current":8.541308,"twenty":-10.153746,"median":-3.674208,"eighty":15.74151,"marketCap":2844255649},{"date":"2025-01-10","current":8.398747,"twenty":-10.15661,"median":-3.674999,"eighty":15.187166,"marketCap":2796782587},{"date":"2025-01-17","current":8.429738,"twenty":-10.15661,"median":-3.674999,"eighty":14.123802,"marketCap":2807102818},{"date":"2025-01-24","current":8.541308,"twenty":-10.15661,"median":-3.674999,"eighty":12.229294,"marketCap":2844255649},{"date":"2025-01-31","current":8.355358,"twenty":-10.15661,"median":-3.674999,"eighty":11.774076,"marketCap":2782334264},{"date":"2025-02-07","current":8.175606,"twenty":-10.15661,"median":-3.674999,"eighty":11.669683,"marketCap":2722476924},{"date":"2025-02-14","current":7.915276,"twenty":-10.15661,"median":-3.674999,"eighty":11.541332,"marketCap":2635786984},{"date":"2025-02-21","current":12.449378,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2639268117},{"date":"2025-02-28","current":11.712888,"twenty":-10.15661,"median":-3.674999,"eighty":11.52593,"marketCap":2483132177},{"date":"2025-03-07","current":11.32214,"twenty":-10.159473,"median":-3.675279,"eighty":11.440344,"marketCap":2400293756},{"date":"2025-03-14","current":10.388159,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2202289726},{"date":"2025-03-21","current":11.045758,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2341700727},{"date":"2025-03-28","current":10.62642,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":2252800958},{"date":"2025-04-04","current":9.263569,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":1963876709},{"date":"2025-04-11","current":8.979147,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1903579170},{"date":"2025-04-17","current":9.09341,"twenty":-10.15661,"median":-3.674999,"eighty":11.484858,"marketCap":1927802871},{"date":"2025-04-24","current":9.417154,"twenty":-10.159473,"median":-3.675279,"eighty":11.489992,"marketCap":1996436690}],"updateTime":1745651350364}}}